Authors
Latest:
Glaxo Vies for a Second Act in HIVA novel joint venture between Glaxo and Pfizer is big on promise. But the combined portfolio and pipeline of HIV drugs? Not so much.
Latest:
The Lesser of Two EvilsIs the American Medical Association's (AMA) Prescribing Data Restriction Program (PDRP) the answer to physicians' privacy concerns, or will it just hamper the relationship between rep and doc? Observant LLC recently gauged reactions to the PDRP and doctors' expectancies of how this initiative affects physicians' practices and their relationships with pharmaceutical representatives. The findings suggest that the initiative may have paradoxical negative implications for physicians.
Latest:
Extension of Medicare is the Affordable Solution to Current Healthcare ProblemsCOVID-19 has only magnified well known flaws of our healthcare system. An extension of Medicare is the affordable solution, writes Bruno Delagneau, and pharma needs to start planning for this to minimize its impact on US revenues.
Latest:
Lifecycle: End GameVery few drugs live forever. Barring remarkable scientific advances and radical market dynamics, most drugs hit old age-and sharply declining sales-several years before their patent expires. But some drugs go out with a bang, not a whimper.
Latest:
Manufacturing’s True North: The Quality CompassThe need for biopharma executives to combine a "culture of quality" with value-added processes and improvements in the area drug manufacturing is critical. Here are steps and strategies than can help.
Latest:
Test and Learn: Making Confident Decisions on the Commercial SideCompanies that adopt this new methodology will have a longstanding competitive advantage over those companies conducting business as usual.
Latest:
Keep Your Pinstripes VerticalThe federal government's enforcement juggernaut rolls on-and the pharmaceutical industry is squarely within its sights. In recent years, the industry has paid close to a billion dollars in fines, civil settlements, and penalties.
Latest:
Retooling the Pharma Marketing ModelIt's time for pharma market research to advance science-based decisions and foster judgement calls
Latest:
Salesforce Survey 2008Welcome to the new employer's market for reps. The Hay Group's annual survey reports how, as the primary sales force contracts, so too does its pay.
Latest:
Good Recruitment Practice = Patient PullPatient recruitment for clinical trials is one of the most significant bottlenecks in drug development. As a result, several organizations have called for the establishment of recruitment best practices, beginning in 2000 with the Office of the Inspector General's (OIG) report on recruiting human subjects and most recently in a Clinical Research Roundtable report published in the March 12, 2003 issue of the Journal of the American Medical Association (JAMA).
Latest:
Lifecycle: End GameVery few drugs live forever. Barring remarkable scientific advances and radical market dynamics, most drugs hit old age-and sharply declining sales-several years before their patent expires. But some drugs go out with a bang, not a whimper.
Latest:
Pharma Comes Under Fire for Jump in Rx PricesDrug manufacturers came under fire at a hearing of the House Energy and Commerce?s health subcommittee for bumping drug prices 10 percent this year. Pharma claims rumors that it?s boosting costs in anticipation of healthcare reform are baseless, but the industry could be facing an uphill battle.
Latest:
Hits Like a BRICThe first wealth is health, wrote American thinker Ralph Waldo Emerson. Indeed, history has taught us (even before Emerson) that health and wealth are inextricably linked-the more money one has, the healthier one is likely to be.
Latest:
Marketing to Professionals: Fax Me!Doctors like direct mail as long as the message is concise and to the point. The minute you ask the doctor to actually do something with the direct mail, that's when your effectiveness starts to go downhill.
Latest:
Legal: E-headacheDocuments from R&D, clinical affairs, regulatory, and sales and marketing can be in the millions. Throw electronic information into the mix, and the number of documents required for litigation increases exponentially.
Latest:
A Fine LineIs a pharma website a type of labeling, a form of advertising, or some new hybrid? The industry has used the internet as a communication channel since 1994, yet, after nearly a decade of online medical development and experimentation, none of the major regulators has decided yet-or offered any clear guidance about-what constitutes "acceptable use."
Latest:
The Growing Pediatrics MarketPediatric drugs require investments in formulation, but the market opportunity is worth the cost.
Latest:
Outsource from the InsideWhen it comes to clinical teams, the question of whether or not to outsource brings some untraditional answers
Latest:
Pharma ConfidentialHow hopeful are execs about the future of their own companies and the industry in general?
Latest:
Outsource from the InsideWhen it comes to clinical teams, the question of whether or not to outsource brings some untraditional answers
